Perioperative use of immunosuppressive medications in patients with Crohn’s disease in the new "biological era"

Amy L. Lightner, Bo Shen

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Crohn’s disease (CD) is characterized by transmural inflammation of the gastrointestinal tract leading to inflammatory, stricturing and/or and fistulizing disease. Once a patient develops medically refractory disease, mechanical obstruction, fistulizing disease or perforation, surgery is indicated. Unfortunately, surgery is not curative in most cases, underscoring the importance of bowel preservation and adequate perioperative medical management. As many of the medications used to treat CD are immunosuppressive, the concern for postoperative infectious complications and anastomotic healing are particularly concerning; these concerns have to be balanced with preventing and treating residual or recurrent disease. We herein review the available literature and make recommendations regarding the preoperative, perioperative and postoperative administration of immunosuppressive medications in the current era of biological therapy for CD. Standardized algorithms for perioperative medical management would greatly assist future research for optimizing surgical outcomes and preventing disease recurrence in the future.

Original languageEnglish (US)
Pages (from-to)165-177
Number of pages13
JournalGastroenterology Report
Issue number3
StatePublished - Aug 1 2017


  • Biological therapy
  • Crohn’s disease
  • Medical management
  • Perioperative period

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Perioperative use of immunosuppressive medications in patients with Crohn’s disease in the new "biological era"'. Together they form a unique fingerprint.

Cite this